Literature DB >> 7593621

Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.

D J Berg1, R Kühn, K Rajewsky, W Müller, S Menon, N Davidson, G Grünig, D Rennick.   

Abstract

Previous studies in vivo have shown that IL-10 infusion can prevent lethal endotoxic shock. Mice deficient in the production of IL-10 (IL10T) were used to investigate the regulatory role of IL-10 in the responses to LPS in three experimental systems. In a model of acute endotoxic shock, it was found that the lethal dose of LPS for IL10T mice was 20-fold lower than that for wild type (wt) mice suggesting that endogenous IL-10 determines the amount of LPS which can be tolerated without death. The high mortality rate of IL10T mice challenged with modest doses of LPS was correlated to the uncontrolled production of TNF as treatment with anti-TNF antibody (Ab) resulted in 70% survival. Additional studies suggested that IL-10 mediates protection by controlling the early effectors of endotoxic shock (e.g., TNF alpha) and that it is incapable of directly antagonizing the production and/or actions of late appearing effector molecules (e.g., nitric oxide). We also found that IL10T mice were extremely vulnerable to a generalized Shwartzman reaction where prior exposure to a small amount of LPS primes the host for a lethal response to a subsequent sublethal dose. The priming LPS dose for IL10T mice was 100-fold lower than that required to prime wt mice implying that IL-10 is important for suppressing sensitization. In agreement with this assumption, IL-10 infusion was found to block the sensitization step. Interestingly, IL-10 was not the main effector of endotoxin tolerance as IL10T mice could be tolerized to LPS. Furthermore, IL-10 infusion could not substitute for the desensitizing dose of LPS. These results show that IL-10 is a critical component of the host's natural defense against the development of pathologic responses to LPS although it is not responsible for LPS-induced tolerance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593621      PMCID: PMC185885          DOI: 10.1172/JCI118290

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

Review 1.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome.

Authors:  C A Dinarello
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis.

Authors:  R G Kilbourn; A Jubran; S S Gross; O W Griffith; R Levi; J Adams; R F Lodato
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

3.  Enzymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol.

Authors:  H H Schmidt; P Wilke; B Evers; E Böhme
Journal:  Biochem Biophys Res Commun       Date:  1989-11-30       Impact factor: 3.575

4.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

Authors:  K Ohlsson; P Björk; M Bergenfeldt; R Hageman; R C Thompson
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

5.  NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide.

Authors:  R G Kilbourn; S S Gross; A Jubran; J Adams; O W Griffith; R Levi; R F Lodato
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 6.  Shwartzman reaction.

Authors:  J P Brozna
Journal:  Semin Thromb Hemost       Date:  1990-10       Impact factor: 4.180

7.  IL-10 inhibits cytokine production by activated macrophages.

Authors:  D F Fiorentino; A Zlotnik; T R Mosmann; M Howard; A O'Garra
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

8.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

Authors:  G Wakabayashi; J A Gelfand; J F Burke; R C Thompson; C A Dinarello
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

9.  A receptor for interleukin 10 is related to interferon receptors.

Authors:  A S Ho; Y Liu; T A Khan; D H Hsu; J F Bazan; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  150 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  Association of sputum parameters with clinical and functional measurements in asthma.

Authors:  E Rosi; G Scano
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 3.  Dual roles for immunity in gastrointestinal cancers.

Authors:  Cristina Ferrone; Glenn Dranoff
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

4.  Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation.

Authors:  Neil R Aggarwal; Kenji Tsushima; Yoshiki Eto; Ashutosh Tripathi; Pooja Mandke; Jason R Mock; Brian T Garibaldi; Benjamin D Singer; Venkataramana K Sidhaye; Maureen R Horton; Landon S King; Franco R D'Alessio
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

5.  Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets.

Authors:  D Haller; S Blum; C Bode; W P Hammes; E J Schiffrin
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

6.  Syndecan-4 as a molecule involved in defense mechanisms.

Authors:  Kazuhiro Ishiguro; Tetsuhito Kojima; Takashi Muramatsu
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

7.  LPS response pattern of inflammatory adipokines in an in vitro 3T3-L1 murine adipocyte model.

Authors:  Salvatore Chirumbolo; Guido Franceschetti; Elena Zoico; Clara Bambace; Luciano Cominacini; Mauro Zamboni
Journal:  Inflamm Res       Date:  2014-02-14       Impact factor: 4.575

8.  IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation.

Authors:  Mira Jung; Yonggang Ma; Rugmani Padmanabhan Iyer; Kristine Y DeLeon-Pennell; Andriy Yabluchanskiy; Michael R Garrett; Merry L Lindsey
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165

Review 9.  The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients.

Authors:  Nicholas S Ward; Brian Casserly; Alfred Ayala
Journal:  Clin Chest Med       Date:  2008-12       Impact factor: 2.878

10.  Competition Between Transients in the Rate of Approach to a Fixed Point.

Authors:  Judy Day; Jonathan E Rubin; Carson C Chow
Journal:  SIAM J Appl Dyn Syst       Date:  2009-11-20       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.